An insight into the early mechanisms of allergen-specific immunotherapy

被引:4
|
作者
Mitsias, Dimitris I. [1 ]
Savvatianos, Savvas [1 ]
Papadopoulos, Nikolaos G. [1 ]
机构
[1] Univ Athens, Dept Allergy, Pediat Clin 2, Athens, Greece
关键词
allergen-specific immunotherapy; apoptosis; desensitization; IDO; indoleamine 2,3-dioxygenase; inhibitory receptor; leukocyte immunoglobulin-like receptor; LILR; rush protocol; tolerance; tryptophan starvation; venom; INHIBITORY RECEPTORS ILT3; T-REGULATORY CELLS; POLLEN IMMUNOTHERAPY; VENOM IMMUNOTHERAPY; IMMUNE DEVIATION; DENDRITIC CELLS; INDUCTION; RESPONSES; DESENSITIZATION; ACTIVATION;
D O I
10.2217/IMT.10.112
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Evaluation of: Bussmann C, Xia J, Allam J-P, Maintz L, Bieber T, Novak N: Early markers for protective mechanisms during rush venom immunotherapy. Allergy 65, 1558-1565(2010). The mechanisms governing the induction of peripheral tolerance as a result of specific immunotherapy are far from being clearly characterized. In the last 15 years, a number of studies have highlighted the tolerogenic role of regulatory T cells, blocking antibodies and anti-inflammatory cytokines such as IL-10 and TGF-beta; however, the best part of our knowledge is mostly limited to mechanisms underlying the maintenance phase. By contrast, little is known regarding the very early effects seen in rush and ultrarush immunotherapy protocols. In this article, Bussmann et al. provide evidence on the possible role, first, of inhibitory receptors of the leukocyte immunoglobulin-like receptor family and, second, of the upregulation of indoleamine 2,3-dioxygenase and subsequent tryptophan starvation on the induction of specific tolerance within a few hours after the initial doses. They also suggest that the observed changes reflect the activation of protective mechanisms, which we are just beginning to understand.
引用
下载
收藏
页码:333 / 336
页数:4
相关论文
共 50 条
  • [41] Allergen-Specific Immunotherapy in Asthma
    Jutel M.
    Current Treatment Options in Allergy, 2014, 1 (2) : 213 - 219
  • [42] Allergen-specific immunotherapy in Georgia
    Rukhadze, M.
    Dolidze, N.
    Abramidze, T.
    Lomidze, N.
    Gotua, M.
    Gamkrelidze, A.
    ALLERGY, 2008, 63 : 529 - 529
  • [43] Advances in Allergen-Specific Immunotherapy
    Passalacqua, Giovanni
    Compalati, Enrico
    Canonica, Giorgio Walter
    CURRENT DRUG TARGETS, 2009, 10 (12) : 1255 - 1262
  • [44] Adjuvants in Allergen-Specific Immunotherapy
    Gajdanowicz, P.
    Pfaar, O.
    Jutel, M.
    ALLERGOLOGIE, 2018, 41 (09) : 427 - 434
  • [45] Novel Administration Routes for Allergen-Specific Immunotherapy: A Review of Intralymphatic and Epicutaneous Allergen-Specific Immunotherapy
    von Moos, Seraina
    Kuendig, Thomas M.
    Senti, Gabriela
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2011, 31 (02) : 391 - +
  • [46] Mechanisms of allergen-specific immunotherapy for allergic rhinitis and food allergies
    Lam, Hiu Yan
    Tergaonkar, Vinay
    Ahn, Kwang Seok
    BIOSCIENCE REPORTS, 2020, 40
  • [47] Mechanisms of Allergen-Specific Immunotherapy and Novel Ways for Vaccine Development
    Jutel, Marek
    Van de Veen, Willem
    Agache, Ioana
    Azkur, Kursat A.
    Akdis, Muebeccel
    Akdis, Cezmi A.
    ALLERGOLOGY INTERNATIONAL, 2013, 62 (04) : 425 - 433
  • [48] Early manifestation of effective allergen-specific immunotherapy (ASIT) in children
    Mingomataj, E.
    Bakiri, A.
    Loloci, G.
    ALLERGY, 2023, 78
  • [49] Allergen-specific immunotherapy for atopic eczema
    Prenzel, F.
    ALLERGOLOGIE, 2016, 39 (10) : 475 - 477
  • [50] Role of immunmodulators in allergen-specific immunotherapy
    Kopp, M. V.
    ALLERGY, 2011, 66 (06) : 792 - 797